`
`Filed: July 20, 2018
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MODERNA THERAPEUTICS, INC.,
`Petitioner,
` v.
`PROTIVA BIOTHERAPEUTICS, INC.,
`Patent Owner.
`_____________________________
`
`Case IPR2018-00739
`Patent 9,364,435
`_____________________________
`
`PATENT OWNER PROTIVA BIOTHERAPEUTICS, INC.’S UPDATED
`MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`in a representative capacity for Patent Owner Protiva Biotherapeautics, Inc.
`(“Protiva”), hereby submits the following mandatory change-of-information
`notices in connection with the petition for inter partes review of U.S. Patent No.
`9,364,435, Case IPR2018-00739.
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Revised
`Patent Owner identifies Arbutus Biopharma Corporation (fka “Tekmira”),
`Genevant Sciences, Ltd. and its fully owned subsidiaries: Genevant Sciences
`Holding, Ltd., Genevant Sciences Corporation, Genevant Sciences, Inc., and
`Genevant Sciences, GmbH. as the real parties-in-interest. Protiva Biotherapeutics,
`Inc. existed as a wholly-owned subsidiary of Arbutus Biopharma Corporation.
`Protiva Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma
`Corporation in January 2018.
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised
`Patent Owner identifies the following related matters:
`Moderna Therapeautics, Inc. v. Protiva Biotherapeutics, Inc., IPR2018-
`00680 regarding U.S. Patent No. 9,404,127; and European Patent Office
`Opposition proceedings regarding EP 2 279 254.
`-2-
`
`
`
`
`
`
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`C. Lead and Back-up Counsel - Unchanged
`D. Electronic Service – Unchanged
`
`Respectfully submitted,
` Date: July 20, 2018
`
`/ Michael T. Rosato /
`
`Michael T. Rosato, Lead Counsel
`
`Reg. No. 52,182
`-3-
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`CERTIFICATE OF SERVICE
`The undersigned certifies that the foregoing Patent Owner Protiva
`Biotherapeutics, Inc.’s Updated Mandatory Notices Under 37 C.F.R. § 42.8 was
`served on July 20, 2018, at the following electronic service addresses:
`Michael Fleming
`C. Maclain Wells
`Alan Heinrich
`IRELL & MANELLA LLP
`mfleming@irell.com
`mwells@irell.com
`aheinrich@irell.com
`ModernaIPR@irell.com
` Date: July 20, 2018
`/ Michael T. Rosato /
`
`
`
`Michael T. Rosato, Lead Counsel
`
`Reg. No. 52,182
`
`-4-
`
`
`
`